Search Results for: ROS1

August 21, 2019

The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson’s Disease (PD).

Publication date: Aug 16, 2019 : Accumulative evidence indicated that the pathologically accumulated metal ions (iron species and Mn) and abnormally up-regulated monoamine oxidase B (MAOB) activity induced oxidation of ... Read more

August 20, 2019August 20, 2019

Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Huntington's Disease Literature

Publication date: Aug 16, 2019 Patient-reported outcomes (PROs) for mental health are important for persons with Huntington disease (HD) who commonly experience symptoms of depression, anxiety, irritability, anger, aggression, and ... Read more

August 20, 2019

Low Vitamin D Linked to Worse Parkinson’s Symptoms

Parkinson's Disease News

Publication date: Aug 17, 2019 Fischmeister, Thomas Foki, Roland BeisteinerAbstractApraxia is a deficit in central motor planning impairing praxis functions such as gesture production or tool use that affects a ... Read more

August 20, 2019August 20, 2019

Long noncoding RNA NORAD regulates MPP+-induced Parkinson’s disease model cells.

Parkinson's Disease Literature

Publication date: Aug 14, 2019 Long non-coding RNAs (lncRNAs) have been demonstrated to play important roles in human diseases. Yet, the functions of lncRNAs in neurodegenerative disorders, such as Parkinson’s ... Read more

August 17, 2019August 17, 2019

Mutant Huntingtin Fails to Directly Impair Brain Mitochondria.

Huntington's Disease Literature

Publication date: Aug 16, 2019 Although the mechanisms by which mutant huntingtin (mHtt) results in Huntington’s disease (HD) remain unclear, mHtt-induced mitochondrial defects were implicated in HD pathogenesis. The effect ... Read more

August 17, 2019August 17, 2019

Implementing group visits for opioid use disorder: A case series.

Opioids Literature

Publication date: Aug 16, 2019 Background: Group-based models of Office-Based Opioid Treatment with buprenorphine-naloxone (B/N) are increasingly being implemented in clinical practice to increase access to care and provide additional ... Read more

August 17, 2019August 17, 2019

Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein.

Parkinson's Disease Literature

Publication date: Aug 14, 2019 Accumulation of α-synuclein (α-Syn) is a remarkable pathology for Parkinson’s disease (PD), therefore clearing it is possibly a promising strategy for treating PD. Aberrant copper ... Read more

August 16, 2019

Auraptene Mitigates Parkinson’s Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species.

Parkinson's Disease Literature

Publication date: Jul 11, 2019 Current therapeutics for Parkinson’s disease (PD) are only effective in providing relief of symptoms such as rigidity, tremors and bradykinesia, and do not exert disease-modifying ... Read more

August 14, 2019August 14, 2019

Stress-induced phospho-ubiquitin formation causes parkin degradation.

Parkinson's Disease Literature

Publication date: Aug 12, 2019 Mutations in the E3 ubiquitin ligase parkin are the most common known cause of autosomal recessive Parkinson’s disease (PD), and parkin depletion may play a ... Read more

August 14, 2019August 14, 2019

Neuroprotective effects of increasing levels of HSP70 against neuroinflammation in Parkinson’s disease model by inhibition of NF-κB and STAT3.

Parkinson's Disease Literature

Publication date: Aug 10, 2019 The present study was aimed to investigate the neuroprotective effect of HSP70 against neuroinflammation in a rotenone-induced Parkinson’s disease model. In the present study, SH-SY5Y ... Read more